Markets

Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9% - Tale of the Tape

Sunesis Pharmaceuticals, Inc. ( SNSS ) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock is now up 26.31% since Jul 17.

None of the estimates for this stock were revised over the past 7 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Sunesis Pharmaceuticals carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

Some better-ranked stocks in the healthcare sector include Actelion Ltd. ( ALIOF ), Cytokinetics, Incorporated ( CYTK ) and Heska Corporation ( HSKA ). All of these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACTELION LTD (ALIOF): Get Free Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

HESKA CORP (HSKA): Free Stock Analysis Report

SUNESIS PHARMA (SNSS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VIRX CYTK HSKA

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More